2,2,2-trifluoro-N-(2-iodo-5-methoxy-phenyl)-acetamide | 439585-89-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2,2-trifluoro-N-(2-iodo-5-methoxy-phenyl)-acetamide
• 英文别名: 2,2,2-trifluoro-N-(2-iodo-5-methoxyphenyl)acetamide；5'-methoxy-2'-iodotrifluoroacetanilide；2-iodo-5-methoxytrifluoroacetanilide；2-iodo-5-methoxy-N-trifluoroacetylaniline
• CAS: 439585-89-4
• 化学式: C₉H₇F₃INO₂
• mdl: MFCD25963472
• 分子量: 345.06
• InChiKey: BFDXRCSYUBIFGO-UHFFFAOYSA-N

物化性质

• 沸点：
  340.5±42.0 °C(Predicted)
• 密度：
  1.865±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,2,2-trifluoro-N-(2-iodo-5-methoxy-phenyl)-acetamide 在 bis-triphenylphosphine-palladium(II) chloride copper(l) iodide 、 potassium carbonate 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 19.0h， 生成 6-methoxy-2-(3-isopropoxy-4-methoxyphenyl)-3-(3,4,5-trimethoxybenzoyl)indole
  参考文献：
  名称：

  一锅合成苯并[b]呋喃和微管蛋白聚合的吲哚抑制剂。

  摘要：

  已经制备了一些最近鉴定的微管蛋白聚合的苯并[b]噻吩抑制剂的苯并[b]呋喃和吲哚类似物，并对其生物活性进行了评估。鉴定了几种非常有效的类似物。

  DOI：

  10.1021/jm020077t
• 作为产物：
  描述：

  2-碘-5-甲氧基苯胺 在 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 以81%的产率得到2,2,2-trifluoro-N-(2-iodo-5-methoxy-phenyl)-acetamide
  参考文献：
  名称：

  Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use

  摘要：

  这项发明涉及由公式I1表示的化合物，以及这些化合物的前药或代谢物，或这些化合物的药用可接受的盐或溶剂，所述前药和所述代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给哺乳动物施用公式I化合物来治疗过度增殖性疾病的方法。

  公开号：

  US20040009965A1

文献信息

• [EN] BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] DERIVES D'AMIDE HETEROARYLE BENZOCONDENSE DE THIENOPYRIDINES UTILISEES EN TANT QU'AGENTS THERAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES D'UTILISATION ASSOCIES
  申请人：PFIZER

  公开号：WO2003106462A1

  公开（公告）日：2003-12-24

  The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  该发明涉及由公式I表示的化合物，以及这些化合物的前药或代谢物，或者这些化合物的药用可接受的盐或溶剂化合物，所述前药和代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的增殖过度性疾病的方法。
• Facile Access to Polysubstituted Indoles via a Cascade Cu-Catalyzed Arylation−Condensation Process
  作者：Yu Chen、Xiaoan Xie、Dawei Ma

  DOI：10.1021/jo702059q

  日期：2007.11.1

  hydrolysis delivered 2,3-disubstituted indoles. The halides bearing a strong electron-withdrawing group in the 4-position can undergo in situ basic hydrolysis to provide the corresponding indoles. Polysubstituted indoles can be prepared from substituted 2-halotrifluoroacetanilides with high regioselectivity.

  CuI / l-脯氨酸催化的2-卤代三氟乙酰苯胺与β-酮酯和酰胺的交叉偶联，然后进行原位酸性水解，生成了2,3-二取代的吲哚。在4-位带有强吸电子基团的卤化物可进行原位碱性水解以提供相应的吲哚。可以由具有高区域选择性的取代的2-卤代三氟乙酰苯胺制备多取代的吲哚。
• Regio- and Chemoselective N-1 Acylation of Indoles: Pd-Catalyzed Domino Cyclization to Afford 1,2-Fused Tricyclic Indole Scaffolds
  作者：Yongxian Liu、Yuanqiong Huang、Hongjian Song、Yuxiu Liu、Qingmin Wang

  DOI：10.1002/chem.201406617

  日期：2015.3.27

  method for the synthesis of 1,2‐fused tricyclic indole scaffolds by domino cyclization involving a Pd‐catalyzed Sonogashira coupling, indole cyclization, regio‐ and chemoselective N‐1 acylation, and 1,4‐Michael addition is reported. This method provides straightforward access to tetrahydro[1,4]diazepino[1,2‐a]indole and hexahydro[1,5]diazocino[1,2‐a]indole scaffolds.

  报道了一种通过多米诺环化反应合成简明方法的方法，该方法涉及多米诺环化反应，该反应涉及Pd催化的Sonogashira偶联，吲哚环化，区域和化学选择性N-1酰化以及1,4-Michael加成。该方法可直接获得四氢[1,4]二氮杂ino [1,2- a ]吲哚和六氢[1,5]二重氮杂酚[1,2- a ]吲哚支架。
• INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：Tatani Kazuya

  公开号：US20130317065A1

  公开（公告）日：2013-11-28

  The present invention provides a compound represented by the general formula (I) of the present invention, which has EP 1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y 1 represents a C 1-6 alkylene group or the like; Y 2 represents a single bond or the like; Z represents —C(═O)—NHSO 2 R 6 , an acidic 5-membered hetero ring group, or the like; R 1 represents a hydrogen atom or the like; R 2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group, or the like; R 4 represents a hydrogen atom, a halogen atom, or the like; R 5 represents a hydrogen atom or the like; and R 6 represents a C 1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种化合物，其表示为本发明的一般式（I），具有EP1受体拮抗作用：其中A代表苯环、吡啶环或类似物；Y1代表C1-6烷基或类似物；Y2代表单键或类似物；Z代表—C(═O)—NHSO2R6、酸性5-成员杂环基团或类似物；R1代表氢原子或类似物；R2代表苯基、5-成员芳香杂环基团或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子、卤原子或类似物；R5代表氢原子或类似物；R6代表C1-6烷基或类似物，或其药学上可接受的盐。此外，本发明的化合物（I）可用作治疗或预防LUTS的药剂，特别是OABs的各种症状。
• INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Kondo Tatsuhiro

  公开号：US20120122931A1

  公开（公告）日：2012-05-17

  A compound represented by the general formula (I) of the present invention, which has an EP 1 receptor antagonism: [wherein A represents a benzene ring or the like; Y represents a C 1-6 alkylene group or the like; R N represents a hydrogen atom or a C 1-6 alkyl group; R 1 represents a hydrogen atom, a C 1-6 alkyl group or the like; R 2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group or the like; R 4 represents a hydrogen atom or the like; and R 5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明的一种以通式(I)表示的化合物，具有EP1受体拮抗作用：[其中A代表苯环或类似物；Y代表C1-6烷基链或类似物；RN代表氢原子或C1-6烷基链；R1代表氢原子、C1-6烷基链或类似物；R2代表苯基，可能有取代基；可能有取代基的5元芳香杂环基，可能有取代基的6元芳香杂环基或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可用作治疗或预防下尿路症状，特别是OAB的各种症状的药剂。